GLUE Stock Analysis: Buy, Sell, or Hold?
GLUE - Monte Rosa Therapeutics, Inc. Common Stock
$20.71
2.04 (10.93%)
▲
5d:
+14.29%
30d:
+9.69%
90d:
+37.79%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GLUE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: GLUE is 7.6% above its trading range ($19.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: GLUE is 7.6% above its trading range ($19.25). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: GLUE is currently trading at $20.71, which is considered extended relative to its 30-day fair value range of $17.18 to $19.25.
Technical Outlook: Technically, GLUE is showing sideways momentum. The price is approaching resistance at $20.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: GLUE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $32.33 (+73.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GLUE is showing sideways momentum. The price is approaching resistance at $20.99. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.9% recently.
Market Sentiment: GLUE has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $32.33 (+73.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$17.18 -
$19.25
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
Protect Your Profits
Holding GLUE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.9%)
- BULLISH: Trading 73.2% below Wall St target ($32.33)
- CAUTION: Extended 7.6% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$17.18 -
$19.25
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$16.15
Resistance Level
$20.99
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.29
Wall Street Target
$32.33
(+73.2%)
Revenue Growth (YoY)
-95.0%
Share & Embed Analysis
Last updated: June 23, 2026 4:51 PM ET
Data refreshes hourly during market hours. Next update: 5:51 PM
Data refreshes hourly during market hours. Next update: 5:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GLUE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Philip Nickson
SELL
5845 shares
2026-04-09
Edmund Dunn
SELL
139 shares
2026-03-04
Edmund Dunn
SELL
536 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
Advanced GLUE Option Strategies
Professional options setups generated by AI based on today's GLUE price and gamma walls.
